Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 5/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5282446 | 0.94 | MAOB (0.41) | MAOBSLC9A1GRIA4MAOAGRM2 | |
| SCHEMBL5275217 | 0.93 | MAOB (0.37) | MAOBSLC9A1GRIA4MAOAGABRB3 | |
| SCHEMBL5282929 | 0.93 | SLC9A1 (0.41) | MAOBSLC9A1MAOAGABRB3GRM2 | |
| SCHEMBL5280477 | 0.90 | SLC9A1 (0.39) | MAOBSLC9A1GRIA4MAOAGABRB3 | |
| SCHEMBL5279198 | 0.89 | SLC9A1 (0.44) | MAOBSLC9A1MAOAGABRB3GRM2 | |
| SCHEMBL5274550 | 0.89 | MAOB (0.40) | MAOBSLC9A1GRIA4MAOAGABRB3 | |
| SCHEMBL5280775 | 0.87 | SLC9A1 (0.42) | MAOBSLC9A1GRIA4MAOAGRM2 | |
| SCHEMBL5276362 | 0.87 | SLC9A1 (0.42) | MAOBSLC9A1GRIA4MAOAGABRB3 | |
| SCHEMBL5286216 | 0.87 | MAOB (0.38) | MAOBSLC9A1GRIA4MAOAGABRB3 | |
| SCHEMBL5283906 | 0.85 | MAOB (0.37) | MAOBSLC9A1GRIA4MAOAGABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020146432-A1 | USE OF AN ANTI-CD45 ANTIBODY DRUG CONJUGATE (ADC) IN CELL THERAPY | Magenta Therapeutics, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
| EP-1859781-A2 | Brightening and/or colouring agent with triazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |